Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The anti-ulcer effect of BPC 157 does not rely on the acid-suppressing mechanism and may provide an alternative for patients who are resistant or intolerant to proton pump inhibitors (PPIs)
BPC-157 works through VEGFR2-Akt-eNOS signaling and nitric oxide production
No serious adverse events have been reported across 100+ studies
Protocol approach 2: gut-focused autoimmune support (BPC-157 plus KPV) Goal: Restore gut barrier integrity and reduce intestinal inflammation Components: BPC-157 : 200-300 mcg twice daily, orally or subcutaneously near the abdomen (promotes mucosal healing, angiogenesis) KPV: 200-500 mcg daily, orally (NF-kB inhibition, cytokine reduction, PepT1-mediated gut absorption) Rationale: For autoimmune conditions with significant gastrointestinal involvement, including IBD, celiac-associated inflammation, or any autoimmune condition complicated by leaky gut, this combination addresses both the physical barrier damage (BPC-157) and the inflammatory signaling (KPV)
